Caribou Biosciences has launched a Phase 1 trial testing its CAR T-cell therapy CB-010 for lupus affecting the kidneys and ...

The Phase 1 GALLOP study evaluating the investigational therapy, CB-010, for treatment of lupus nephritis has launched.

About 100 days into the CEO role at Kyverna Therapeutics, Warner Biddle has determined the strategic priorities for the ...

Aurinia Pharma and partner Otsuka have secured approval in the EU for Lupkynis, billed as the first oral treatment for active nephritis in patients with the autoimmune disease systemic lupus ...

United States of America Background Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), associated with considerable morbidity and an increased risk of end-stage ...

Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will present its ...

Glomerulonephritis (GN), a severe kidney condition impacting glomeruli, can lead to complications like high blood pressure, ...

Researchers identify a pathogenic subset of CD8+ memory T-cells that promote airway tissue inflammation and recurrent ...

Caribou Biosciences (CRBU) announced initiation of the GALLOP Phase 1 clinical trial evaluating CB-010 in patients with lupus nephritis and ...

"I am thrilled to represent Autoimmunity BioSolutions at the Sequire Investor Summit in Puerto Rico and to continue ...

Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative ...

Aurinia Pharmaceuticals (AUPH) released its third-quarter results, reporting solid revenue growth and robust cash flow from ...